Schwab Gisela 4
4 · EXELIXIS, INC. · Filed Feb 19, 2021
Insider Transaction Report
Form 4
EXELIXIS, INC.EXEL
Schwab Gisela
EVP & Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2021-02-17$1.70/sh+50,000$85,000→ 590,597 total - Sale
Common Stock
2021-02-17$22.50/sh−50,000$1,125,000→ 540,597 total - Exercise/Conversion
Common Stock
2021-02-18$1.70/sh+50,000$85,000→ 590,597 total - Sale
Common Stock
2021-02-18$22.35/sh−50,000$1,117,500→ 540,597 total - Exercise/Conversion
Option (right to buy)
2021-02-17−50,000→ 150,000 totalExercise: $1.70From: 2015-07-20Exp: 2021-09-18→ Common Stock (50,000 underlying) - Exercise/Conversion
Option (right to buy)
2021-02-18−50,000→ 100,000 totalExercise: $1.70From: 2015-07-20Exp: 2021-09-18→ Common Stock (50,000 underlying)
Holdings
- 14,880(indirect: By 401(k))
Common Stock
Footnotes (3)
- [F1]Includes 171,083 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
- [F2]Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of February 17, 2021.
- [F3]The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.